Why SpyGlass Pharma, Inc.’s (SGP) Stock Is Up 6.35%
As of Wednesday, August 19, SpyGlass Pharma, Inc.’s SGP share price has surged by 6.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
Commentary & Analysis
Why SpyGlass Pharma, Inc.’s (SGP) Stock Is Down 5.06%
As of Friday, July 31, SpyGlass Pharma, Inc.’s SGP share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why SpyGlass Pharma, Inc.’s (SGP) Stock Is Up 6.21%
As of Thursday, July 30, SpyGlass Pharma, Inc.’s SGP share price has surged by 6.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why SpyGlass Pharma, Inc.’s (SGP) Stock Is Down 7.79%
As of Monday, July 13, SpyGlass Pharma, Inc.’s SGP share price has dipped by 7.79%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why SpyGlass Pharma, Inc.’s (SGP) Stock Is Down 10.61%
As of Monday, July 13, SpyGlass Pharma, Inc.’s SGP share price has dipped by 10.61%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | SGP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $877.3 | $618.0 | 43% |
|
| Shares Out (Mil) | 33.4 | 44.8 | 39% |
|
| Institutional Ownership | 81.9% | 85.3% | 50% |
|
| Float (Mil) | 6.5 | 47.4 | 14% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 72 | 390 | 31% |
|
| Price Change (52-week) |
na | 68.6% | na |
|
| Growth | SGP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.621) | ($2.481) | ($2.717) | |
| Month Ago EPS | ($0.583) | ($2.313) | ($2.697) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.583) | ($2.313) | ($2.697) | |
| Year/Year Chg | 4.5% | (86.2%) | (82.9%) | |
| Financials | SGP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($56) | ($11) | 15% |
|
| EPS (TTM) | ($3.879) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($6) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $186 | $5 | 83% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 19% |
|
| Enterprise Value (Q1) (Mil) | $614 | $450 | 36% |
|
| Valuation | SGP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.77 | 2.78 | 71% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SGP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (46.1%) | (22.4%) | 12% |
|
| ROE | (65.2%) | (20.2%) | 13% |
|
| Liabilities to Assets | 4.5% | 32.2% | 2% |
|
| F-Score | 1 | 3 | na |
|
SpyGlass Pharma, Inc. did not pass any screens on 8/20/2026.
